Prediction model for hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitors

被引:21
|
作者
Choi, Yong Jun [1 ]
Kim, Taehee [1 ]
Kim, Eun Young [1 ]
Lee, Sang Hoon [1 ]
Kwon, Do Sun [1 ]
Chang, Yoon Soo [1 ]
机构
[1] Yonsei Univ, Dept Internal Med, Coll Med, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
Hyperprogressive disease; NSCLC; PD-L1; inhibitor; prognosis; BONE-MARROW; SURVIVAL; NIVOLUMAB; DOCETAXEL; BLOCKADE;
D O I
10.1111/1759-7714.13594
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Hyperprogressive disease (HPD) is a paradoxical acceleration of tumor growth after immune checkpoint inhibitor (ICI) treatment. This study aimed to identify the risk factors and to present a predictive model for HPD in patients treated with ICIs. Methods A total of 78 non-small cell lung cancer (NSCLC) cases, treated with at least two cycles of ICIs who underwent computed tomography (CT) for response assessment were recruited into the study from January 2016 to August 2019. HPD was defined by the following criteria: (i) time-to-treatment failure <2 months; (ii) a 50% increase in the sum of target lesion diameters; (iii) new development of at least two lesions in an already involved organ; (iv) appearance of a new organ lesion; and (v) a decrease in ECOG PS 2. Results Of the 78 total patients, 15 (19.2%) had HPD. The risk factors of HPD were age; primary lesion size; and metastases in the contralateral lung, pleura, liver, and bone in multivariable logistic regression (odds ratio [OR]; 0.9038, 1.6619, 28.5913, 23.8264, 14.5711, and 20.1533, respectively, allP-values < 0.05). By using these risk factors, we developed a prediction model for HPD and the area under the receiver operating characteristic curve of the model was 0.9556 (95% confidence interval [CI]: 0.9133-0.9978). Conclusions HPD is relatively common and associated with a grave clinical outcome, requiring a careful monitoring in lung cancer patients treated with ICIs. Moreover, risk factors such as age, size of tumor and number of various metastatic lesions should be taken into consideration before ICI administration. Key pointsSignificant findings of the study Age, primary lesion size, and number of metastases are risk factors of HPD. HPD is strongly associated with poor prognosis. HPD during ICI use needs comprehensive monitoring. What this study adds This is the first study to develop a prediction model. The area under the curve of the prediction model for HPD was 0.9556.
引用
收藏
页码:2793 / 2803
页数:11
相关论文
共 50 条
  • [21] Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
    Qiu, Zhenbin
    Chen, Zihao
    Zhang, Chao
    Zhong, Wenzhao
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2019, 8 (01)
  • [22] Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer
    Bote, Helena
    Mesas, Andres
    Baena, Javier
    Herrera, Mercedes
    Paz-Ares, Luis
    EXPERT OPINION ON EMERGING DRUGS, 2022, 27 (03) : 289 - 300
  • [23] Immune Checkpoint Inhibitors in Oncogenic Driven Non-small Cell Lung Cancer
    Fonseca, A.
    Silva, E.
    Coutinho, D.
    Campainha, S.
    Dias, M.
    Barroso, A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S339 - S340
  • [24] Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
    Soh, Junichi
    Hamada, Akira
    Fujino, Toshio
    Mitsudomi, Tetsuya
    CANCERS, 2021, 13 (16)
  • [25] Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Ushio, Ryota
    Murakami, Shuji
    Saito, Haruhiro
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (07)
  • [26] Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Jung, Chi Young
    Antonia, Scott J.
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2018, 81 (01) : 29 - 41
  • [27] Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer
    Lin, Gen
    Wang, Zhijie
    Chu, Qian
    Hu, Yi
    Huang, Dingzhi
    Wang, Jun
    Yang, Fan
    Zhong, Wenzhao
    Zhou, Chengzhi
    Zhu, Bo
    Ai, Xinghao
    Cao, Baoshan
    Cao, Yabing
    Chen, Mingqiu
    Chen, Xiaohui
    Chu, Tianqing
    Duan, Jianchun
    Fan, Yun
    Fang, Yong
    Feng, Shuitu
    Feng, Weineng
    Guo, Hui
    Han, Chengbo
    He, Yong
    Hong, Shaodong
    Hu, Jie
    Huang, Meijuan
    Huang, Yan
    Jiang, Da
    Jiang, Kan
    Jiang, Richeng
    Jin, Bo
    Jin, Shi
    Li, Jisheng
    Li, Min
    Li, Ziming
    Li, Chao
    Lin, Jie
    Liu, Anwen
    Liu, Si-Yang Maggie
    Yutao, Liu
    Liu, Zhefeng
    Liu, Zhe
    Liu, Zhenhua
    Liu, Zhentian
    Liu, Zhigang
    Lu, Yuping
    Lv, Tangfeng
    Ma, Zhiyong
    Miao, Qian
    THORACIC CANCER, 2024, 15 (05) : 419 - 426
  • [28] Chronological Effects of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Guo, Xinyue
    Qin, Lanqun
    Wang, Xinmeng
    Geng, Qian
    Li, Dongqing
    Lu, Yingying
    Jiang, Hua
    IMMUNOLOGY, 2025, 174 (04) : 402 - 410
  • [29] The role of immune checkpoint inhibitors in advanced non-small cell lung cancer
    Pistamaltzian, Nikolaos F.
    Georgoulias, Vassilis
    Kotsakis, Athanasios
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2019, 13 (05) : 435 - 447
  • [30] Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
    Miura, Yosuke
    Kasahara, Norimitsu
    Sunaga, Noriaki
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S628 - S632